Altium Capital

Healthcare is the only sector this New York investment manager works in, and within it the money goes mostly to therapeutics. Altium Capital Management describes itself as an alternative investment manager providing growth capital to private and public companies that are developing new technologies for human health, with a long term view of each holding.

The kind of company it backs

The firm's universe is concentrated in private ventures and in small cap and micro cap public companies. It looks for businesses with transformative catalysts ahead of them, and many are raising money from institutional investors for the first time. Its capital reaches early stage ventures still in pre-clinical development, and the stated intention is a lasting partnership with several rounds of financing into the same company. It also says it helps portfolio companies attract further capital through a network of like minded investors, and that its own research and due diligence is what gives it confidence to invest for the long haul.

Who does the analysis

The firm says its chief executive has more than 20 years of experience investing in healthcare through hedge funds, private equity and venture capital. Its team mixes scientific professionals with experienced fund managers, and the site describes the aim as combining that scientific and financial insight to produce superior returns over time. It also describes a collaborative culture and says it hires people who want to learn and build a career there.

Selected portfolio companies

Its site names a group of portfolio holdings, each described in the company's own terms:

• Antios Therapeutics, founded in 2018, which develops therapies to treat and cure viral diseases.
• Cerevel Therapeutics, working on new treatment options for neuroscience diseases.
• Chemomab Therapeutics, a clinical stage biotech company targeting conditions that involve inflammation and fibrosis.
• eGenesis, which aims to end the shortage of organs for transplant.
• Gemini Therapeutics, developing precision medicine for dry age related macular degeneration.
• Hyperfine, which wants to put MR imaging within reach of patients in any healthcare facility.
• Immunovant, a clinical stage company focused on autoimmune disease.
• Ocuphire Pharma, developing therapies for eye disorders.
• Palisade Bio, advancing oral therapies for digestive complications after surgery.
• Quoin, a specialty pharmaceutical company working on rare and orphan diseases.
• Sagimet Biosciences and Hummingbird Bioscience, the latter built on an antibody discovery platform aimed at cancer and autoimmune disease.

Altium Capital is an alternative investment manager based in New York. Its work centres on long-term investment in healthcare companies developing new technologies for human health. It supplies growth capital to both private and public companies.

Services

• Growth capital: funding for early-stage ventures, including those still in pre-clinical development.
• Repeat financing: long-term partnerships with several rounds of investment in the same company.
• Capital introductions: help attracting further investors through its network.
• Research-led selection: investment decisions rest on its own research and due diligence.

Who it works with

Mostly therapeutics businesses, whether private ventures or small-cap and micro-cap listed companies, many of them raising money from institutions for the first time. Portfolio names shown include Antios Therapeutics, Cerevel Therapeutics, Chemomab Therapeutics, eGenesis and Immunovant.

Key facts

• Based in: New York
• Sector: healthcare
• Chief executive: Jacob Gottlieb, with more than 20 years in healthcare investing